Evidence map›Paper›PMID 34591230›Full record

ArticleEndocrine2022

Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.

Meichen Wang, Changwei Wang, Chao Feng, Wanrong Guo, Huan Chen, Bing Liu, Enxiao Li, Wei Liu, Adam Taouil, Iwao Ojima and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Meichen Wang *Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Changwei Wang *Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, USA.
Chao FengKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Wanrong GuoGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 510530, Guangzhou, China.
Huan ChenBioBank, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Bing LiuBioBank, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China.
Enxiao LiDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Wei LiuUltrasound Diagnosis Center, Shaanxi Provincial People's Hospital, 710068, Xi'an, China.
Adam TaouilDepartment of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, USA.
Iwao OjimaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, USA. iwao.ojima@stonybrook.edu.ORCID http://orcid.org/0000-0002-3628-1161
Peng HouKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, China. phou@xjtu.edu.cn.ORCID http://orcid.org/0000-0001-7010-7944
First Affiliated Hospital of Xi'an Jiaotong University · CNChinese Academy of Sciences · CNStony Brook University · USShanxi Medical University · CN

Funding

Tumor -Targeting Chemotherapeutic AgentsR01CA103314 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI OJIMA, IWAO · 2003 to 2013
$3.1M
innovation talent promotion plan in shaanxi province No. 2018TD-006national natural science foundation of china No. 82072949NCI NIH HHS R01 CA103314
6 · The paper itself

Abstract

purposeAnaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancers and it is rapidly fatal without any effective therapeutic regimens. There are some clinical trials showing that paclitaxel-based chemotherapy for ATC can achieve a relatively high response rate and low incidence of adverse reaction. The aim of this study was to evaluate potential therapeutic activity of novel taxoids in ATC cells.

methodsWe evaluated antitumor activity of five novel 3'-difluorovinyltaxoids (DFV-taxoids) in anaplastic thyroid cancer cells by a series of in vitro and in vivo experiments. Besides, we also explored the potential mechanism underlying the difference among the taxoids and paclitaxel by molecular docking and tubulin polymerization assays.

resultsOur data showed that these novel DFV-taxoids were more effective than paclitaxel in ATC cell lines and xenografts, as reflected by the inhibition of cell proliferation, colony formation and tumorigenic potential in nude mice, and the induction of G

conclusionsOur data demonstrate that these novel taxoids exhibit stronger antitumor activity in ATC cells than paclitaxel, thereby providing a promising therapeutic strategy for the patients with ATC.

Indexed as

Antineoplastic AgentsThyroid Carcinoma, AnaplasticThyroid NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceMice, NudeMolecular Docking SimulationTaxoidsAntineoplastic AgentsTaxoidsAnaplastic thyroid cancer (ATC)Antitumor effectNovel taxoidsPaclitaxel

Identifiers

PMID34591230
OpenAlexW3177625256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.